Cytek Biosciences annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Cytek Biosciences Depreciation & Amortization Growth & History (CTKB)
Cytek Biosciences's depreciation and amortization was $7.6M for fiscal 2025.
View full Cytek Biosciences company overviewCytek Biosciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.6M | $367,000 | +5.09% |
| 2024 | 2024-12-31 | $7.2M | $1.2M | +19.25% |
| 2023 | 2023-12-31 | $6.0M | $3.6M | +142.70% |
| 2022 | 2022-12-31 | $2.5M | $1.3M | +100.64% |
| 2021 | 2021-12-31 | $1.2M | $639,000 | +105.97% |
| 2020 | 2020-12-31 | $603,000 | — | — |
Cytek Biosciences quarterly depreciation and amortization
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.0M | $119,000 | +6.30% |
| Q1 2026 | 2026-03-31 | $1.9M | −$10,000 | −0.53% |
| Q4 2025 | 2025-12-31 | $3.0M | — | — |
| Q3 2025 | 2025-09-30 | $1.9M | $67,000 | +3.62% |
| Q2 2025 | 2025-06-30 | $1.9M | $82,000 | +4.54% |
| Q1 2025 | 2025-03-31 | $1.9M | $176,000 | +10.36% |
| Q3 2024 | 2024-09-30 | $1.9M | $84,000 | +4.75% |
| Q2 2024 | 2024-06-30 | $1.8M | $159,000 | +9.64% |
| Q1 2024 | 2024-03-31 | $1.7M | $698,000 | +69.73% |
| Q3 2023 | 2023-09-30 | $1.8M | $1.7M | +2354.17% |
| Q2 2023 | 2023-06-30 | $1.6M | $784,000 | +90.64% |
| Q1 2023 | 2023-03-31 | $1.0M | $207,000 | +26.07% |
| Q3 2022 | 2022-09-30 | $72,000 | −$117,000 | −61.90% |
| Q2 2022 | 2022-06-30 | $865,000 | $664,000 | +330.35% |
| Q1 2022 | 2022-03-31 | $794,000 | $627,000 | +375.45% |
| Q3 2021 | 2021-09-30 | $189,000 | $10,000 | +5.59% |
| Q2 2021 | 2021-06-30 | $201,000 | $40,000 | +24.84% |
| Q1 2021 | 2021-03-31 | $167,000 | — | — |
| Q3 2020 | 2020-09-30 | $179,000 | — | — |
| Q2 2020 | 2020-06-30 | $161,000 | — | — |
Cytek Biosciences depreciation and amortization trends
Over the last five fiscal years, Cytek Biosciences's depreciation and amortization increased from $603,000 to $7.6M, a change of $7.0M. The latest reported quarter, Q2 2026, shows $2.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytek Biosciences source filings ↗